AIM: To quantify circulating fibroblast activation protein (cFAP) and dipeptidyl peptidase 4 (cDPP4) protease activities in patients with rheumatoid arthritis (RA), systemic sclerosis (SSc), and a control group with mechanical back pain and to correlate plasma levels with disease characteristics. METHODS: Plasma was collected from patients with RA (n = 73), SSc (n = 37) and control subjects (n = 26). DPP4 and FAP were quantified using specific enzyme activity assays. RESULTS: Median cDPP4 was significantly lower in the RA group (P = 0.02), and SSc group (P = 0.002) compared with controls. There were no significant differences in median cFAP between the three groups. DPP4 and FAP demonstrated a negative correlation with inflammatory markers and duration of disease. There were no associations with disease subtypes in RA, including seropositive and erosive disease. Decreased cDPP4 was found in SSc patients with myositis. Plasma FAP was lower in RA patients receiving prednisone (P = 0.001) or leflunomide (P = 0.04), but higher with biologic agents (P = 0.01). RA patients receiving leflunomide also had decreased cDPP4 (P = 0.014). SSc patients receiving prednisone (P = 0.02) had lower cDPP4 but there was no association with cFAP. CONCLUSIONS: No association was found between cFAP and RA or SSc. Plasma DPP4 was decreased in RA and SSc when compared with controls. cDPP4 and cFAP correlated negatively with inflammatory markers and there were no significant correlations with disease characteristics in this RA cohort.
AIM: To quantify circulating fibroblast activation protein (cFAP) and dipeptidyl peptidase 4 (cDPP4) protease activities in patients with rheumatoid arthritis (RA), systemic sclerosis (SSc), and a control group with mechanical back pain and to correlate plasma levels with disease characteristics. METHODS: Plasma was collected from patients with RA (n = 73), SSc (n = 37) and control subjects (n = 26). DPP4 and FAP were quantified using specific enzyme activity assays. RESULTS: Median cDPP4 was significantly lower in the RA group (P = 0.02), and SSc group (P = 0.002) compared with controls. There were no significant differences in median cFAP between the three groups. DPP4 and FAP demonstrated a negative correlation with inflammatory markers and duration of disease. There were no associations with disease subtypes in RA, including seropositive and erosive disease. Decreased cDPP4 was found in SSc patients with myositis. Plasma FAP was lower in RApatients receiving prednisone (P = 0.001) or leflunomide (P = 0.04), but higher with biologic agents (P = 0.01). RApatients receiving leflunomide also had decreased cDPP4 (P = 0.014). SSc patients receiving prednisone (P = 0.02) had lower cDPP4 but there was no association with cFAP. CONCLUSIONS: No association was found between cFAP and RA or SSc. Plasma DPP4 was decreased in RA and SSc when compared with controls. cDPP4 and cFAP correlated negatively with inflammatory markers and there were no significant correlations with disease characteristics in this RA cohort.
Authors: Shirley Uitte de Willige; Joyce J M C Malfliet; Jaap W Deckers; Diederik W J Dippel; Frank W G Leebeek; Dingeman C Rijken Journal: Int J Cardiol Date: 2014-10-22 Impact factor: 4.164
Authors: Kyung N Lee; Kenneth W Jackson; Victoria J Christiansen; Chung S Lee; Jin-Geun Chun; Patrick A McKee Journal: Blood Date: 2005-10-13 Impact factor: 22.113
Authors: Stephanie Lefèvre; Anette Knedla; Christoph Tennie; Andreas Kampmann; Christina Wunrau; Robert Dinser; Adelheid Korb; Eva-Maria Schnäker; Ingo H Tarner; Paul D Robbins; Christopher H Evans; Henning Stürz; Jürgen Steinmeyer; Steffen Gay; Jürgen Schölmerich; Thomas Pap; Ulf Müller-Ladner; Elena Neumann Journal: Nat Med Date: 2009-11-08 Impact factor: 53.440
Authors: Stefan Bauer; Michael C Jendro; Andreas Wadle; Sascha Kleber; Frank Stenner; Robert Dinser; Anja Reich; Erica Faccin; Stefan Gödde; Harald Dinges; Ulf Müller-Ladner; Christoph Renner Journal: Arthritis Res Ther Date: 2006 Impact factor: 5.156
Authors: Shirley Uitte de Willige; Fiona M Keane; David G Bowen; Joyce J M C Malfliet; H Emma Zhang; Bharvi Maneck; Geoffrey W McCaughan; Frank W G Leebeek; Dingeman C Rijken; Mark D Gorrell Journal: PLoS One Date: 2017-06-05 Impact factor: 3.240
Authors: Cecy R Xi; Arianna Di Fazio; Naveed Ahmed Nadvi; Karishma Patel; Michelle Sui Wen Xiang; Hui Emma Zhang; Chandrika Deshpande; Jason K K Low; Xiaonan Trixie Wang; Yiqian Chen; Christopher L D McMillan; Ariel Isaacs; Brenna Osborne; Ana Júlia Vieira de Ribeiro; Geoffrey W McCaughan; Joel P Mackay; W Bret Church; Mark D Gorrell Journal: Molecules Date: 2020-11-18 Impact factor: 4.411
Authors: Simone E Jaenisch; Catherine A Abbott; Mark D Gorrell; Peter Bampton; Ross N Butler; Roger Yazbeck Journal: Clin Transl Gastroenterol Date: 2022-01-19 Impact factor: 4.396